CHWY Earnings

CHWY reported its FY2026Q3 earnings on 2025-12-10, showcasing a revenue of 3.00B against an estimate of 3.00B, resulting in a 0.66% surprise. The EPS was 0.32, surpassing the expected 0.3 by 6.67% . The stock experienced a 1.52% price change on the earnings day and a -4.88% change over the next five days, reflecting market reactions to the results.

Following CHWY's FY2026Q3 earnings announcement on 2025-12-10, the stock price moved by 1.52% on the day of the release. Over the subsequent five days, it saw a -4.88% change. Historically, CHWY's stock price tends to shift by an average of -0.71% in the 10 days leading up to earnings and +0.18% in the 10 days following, providing insight into potential market.

For 2026/Q4, analysts estimate CHWY’s annual revenue to reach 3.00B, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.19% and EPS estimates Revise Upward by 0.12% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CHWY's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 0.19%, while EPS estimates moved Revise Upward by 0.12% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CHWY's stock price typically moves by -0.71% in the 10 days before its earnings and +0.18% in the 10 days after. For the upcoming 2026/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 3.00B.

The earnings call summary presents a mixed picture. The financial performance and shareholder return plans are average, with no major surprises. Market strategy and product development updates show potential but lack immediate impact. The Q&A section reveals some uncertainties, particularly regarding settlement payments and management's vague responses. While there are positive aspects like private label progress, the overall sentiment remains cautious, leading to a neutral rating. Without specific market cap data, the stock reaction is expected to be mild.